Shanghai hormonal and nervous system prices fell by an average of 14%

Recently, the Shanghai Municipal Price Bureau and other departments issued a notice to adjust the maximum retail price of related drugs sold in the administrative area of ​​the city today, according to the requirements of the National Development and Reform Commission. It is understood that the average price reduction rate is 14%.

The notice stated that the reduction of some hormones and the adjustment of the highest retail prices of drugs such as endocrine and nervous system. Cancellation of production and import of recombinant human growth hormone injection produced by Novo Nordisk Corporation, gestrinone capsule produced by British Russell Limited, clodronate disodium tablet manufactured by Bayer, and Pfizer’s Prices for separate pricing of products such as ergoline injections; cancellation of the uniform pricing of Ami Triazin® and the price of individual pricing. The relevant drug prices announced this time are the highest retail prices. The sales prices of all types of medical and health institutions, social retail pharmacies, and other pharmaceutical production and business entities at all levels within the administrative area of ​​this Municipality shall not exceed the stipulated maximum retail price. Encourage various types of drug dealers to further reduce their actual retail prices by improving management and reducing operating costs. The price of specific drugs can be found on the website of the Shanghai Development and Reform Commission.

Previously, the National Development and Reform Commission had issued a notice in advance and decided to reduce the maximum retail prices of some hormones, endocrine and nervous system drugs, etc., starting from September 1. A total of 82 varieties and 400 dosage forms were involved, and the average price cuts At 14%, the magnitude and scope of the price cuts in Shanghai were consistent with the national requirements.